BOARD OF DIRECTORS
Date：2020-02-21
Executive Directors
Mr. LONG Jing, aged 49, is the chairman of the Board and executive director of the Company. Mr. Long joined the Company in July 2005 and served as the manager of sales management department and vice-general manager of sales of the Company until August 2018. He was the chief executive officer of the Company from August 2018 to March 2021. He has been an executive director of the Company since December 2018 to date, a director of Shandong Weigao Orthopaedic Device Company Limited (stock code: 688161) from March 2020 to date and the chairman of the Board of the Company from March 2021 to date. Prior to joining the Company, Mr. Long served as the sales chief of 山東省塑料工業總公司 (Shandong Plastic Materials Industry Company*) from 1996 to 2002. Mr. Long obtained a bachelor degree in marketing from Shandong Economic University and a master degree in business administration from Shandong University. He also obtained the Chinese professional qualification of Certified Public Accountant (CPA), with nearly 20 years of experiences in sales and operation management in the medical device industry.
Mr. CONG Rinan, aged 42, the executive director and chief executive officer of the Company. Mr. Cong joined the Company in August 2003. He served as supervisor, deputy manager and manager of the syringe production workshop until December 2013. During the period from January 2014 to December 2014, Mr. Cong served as the assistant to the chief executive officer of the Company. From January 2015 to December 2018, he served as the deputy general manager of the clinical care business unit of the Company; from January 2019 to March 2021, he has been the general manager of the clinical care business unit; he has been the chief executive officer of the Company from March 2021 until present; he has been the executive director of the Company from May 2021 until present. Mr. Cong obtained a bachelor’s degree in applied chemistry from Yantai University and a master’s degree in engineering from Harbin Institute of Technology. He completed the Master of Business Administration (MBA) program at Renmin University of China in 2019 and obtained the title of senior engineer of medical device professional, with nearly 20 years of experience in production and operation management in the medical device industry.
Mr. LU Junqiang, aged 49, a director and a general manager of Shandong Weigao Orthopaedic Device Company Limited (stock code: 688161). Mr. Lu joined Weigao Orthopaedic in January 2018 as the deputy general sales manager of Weigao Orthopaedic and has been the director and general manager of Weigao Orthopaedic in September 2018 and from September 2019 to present. Prior to joining Weigao Orthopaedic, Mr. Lu served as the regional manager, sales manager of Eastern China and deputy general manager of the medical devices products business division of the Group since October 2000. Mr. Lu obtained a master’s degree of business administration from the University of Wales in the United Kingdom and has more than 20 years of experience in sales and operation management in the medical device industry.
Mr. NI Shili, aged 61, a director and a general manager of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd.. Mr. Ni joined the Company in May 1995. He worked as the product sales manager for the infusion sets of the Company until December 2004 and product sales manager for pharma packaging materials of the Company from January 2005 to March 2009, respectively. He serves as the general manager of the pharma packaging materials division since April 2009 to date. Mr. Ni graduated from Heilongjiang Radio and TV University majoring in marketing and is a professional intermediate engineer in medical technology with nearly 30 years of sales and operation management experience in the medical device and pharma packaging industry.
Non-executive Directors
Mr. TANG Zhengpeng, aged 52, is the vice chairman of the Board and a non-executive director of the Company. Mr. Tang joined the Weigao Holding in December 2017 and currently is a director of Weihai Weigao International Medical Investment Holdings Co., Ltd. and the vice chairman of Weigao Holding; and a director and vice chairman of Weihai Huadong Automation Co., Ltd (a company listed on the Shenzhen Stock Exchange, stock code 002248) in March 2018 and from July 2018 to pressure. Prior to joining Weigao Holding, Mr. Tang was the assistant to the president of Bank of Communications, Weihai Branch, the president of Minsheng Bank, Weihai Branch and the assistant to the president of China Minsheng Bank, Qingdao Branch. Mr. Tang graduated from Shandong University majoring in business administration and completed the EMBA program of China Europe International Business School in 2019, with over 20 years of experience in banking and corporate finance management.
Mr. CHEN Lin, aged 47, is a non-executive director of the Company. Mr. Chen joined Weigao Holding in September 2000 and has served as assistant general manager and general manager of Weigao Holding and currently is a director of Weihai Weigao International Medical Investment Holdings Co., Ltd. and the chairman of Weigao Holding. Mr. Chen graduated from Shandong University, Weihai with a degree in economic management and completed a Master of Business Administration (MBA) program at Renmin University of China in 2004, with over 20 years of operation management experience in the medical device industry.
Independent Non-executive Directors
Mr. LI Guohui, aged 51, an independent non-executive director of the Company and joined the Company in 2022. Mr. Li is currently the chief strategy officer and co-chief financial officer of China Aircraft Leasing Group (“CAL”), a company listed on the Stock Exchange, stock code: 1848). From July 2019 to December 2022, Mr. Li held position in Zhongsheng Group Holdings Limited (“Zhongsheng Holdings”) (a company listed on the Stock Exchange, stock code: 0881) and currently serves as an executive director and joint chief financial officer of Zhongsheng Holdings. From August 2013 to July 2019, Mr. Li was the vice president, chief financial officer and executive director of China Resources Pharmaceutical Group Limited (a company listed on the Stock Exchange, stock code: 3320), a non-executive director of Dong-E E-Jiao Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000423) and China Resources Double Crane Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 600062) and a supervisor of Sanjiu Medical & Pharmaceutical Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000999). From September 2009 to August 2013, he was the accounting director of the finance department of China Resources (Holdings) Company Limited. From April 2006 to September 2009, he was a senior analyst of IMC Development Management Company Limited in Hong Kong. From October 2005 to April 2006, he was a M&A investment analyst in IMC Fanya, Singapore. Mr. Li obtained a bachelor’s degree in naval architecture and marine engineering from Wuhan University of Technology, a master’s degree in business administration from Wuhan University, a master’s degree in financial management from Nanyang Technological University in Singapore and obtained professional qualifications as a Chartered Financial Analyst (CFA) qualified by the CFA Institute of Chartered Financial Analyst and a Certified Public Accountant (CPA) qualified by the Singapore Institute of Chartered Accountants.
Mrs. MENG Hong, aged 56, an independent non-executive director of the Company and joined the Company in 2022. Mrs. Meng is currently an associate professor of the Accounting Department of the Business School of Shandong University (Weihai). She has over 20 years of experience in research and teaching at university. From 1994 to 1999, Ms. Meng worked at Auditing Firm of Weihai High-tech Industrial Development Zone （威海高技術產業開發區審計師事務所）, where she was responsible for auditing and appraising. From 2012 to 2018, Mrs. Meng served as an independent director of Shandong New Beiyang Information Technology Co., Ltd (stock code: 002376.SZ). From 2016 to 2022, she served as an independent director of Shandong Weida Machinery Co., Ltd. (stock code: 002026.SZ) and Zhuhai Winbase International Chemical Tank Terminal Co., Ltd. (stock code: 002492.SZ). Currently, Ms. Meng is also an independent director of Sunfly Intelligent Technology Co., Ltd. (stock code: 300423. SZ), Weihai Guangwei Composite Co., Ltd. (stock code: 300699.SZ) and Tianrun Industrial Technology Co., Ltd (stock code: 002283.SZ). Ms. Meng obtained a bachelor’s and master’s degree in economics from Shandong University and a doctorate degree in economics from Hoseo University in South Korea. She is an asset appraiser in China.
Mr. LI Qiang, aged 47, an independent non-executive director of the Company and joined the Company in 2022. Mr. Li is currently the managing partner of Grandall Law Firm (Shanghai). Mr. Li is mainly engaged in the legal practice of capital markets, including private equity investment, corporate listing and M&A restructuring. Mr. Li is also the director of the Securities Business Research Committee of the Shanghai Bar Association and an arbitrator of Shanghai Arbitration Commission. Prior to joining Grandall Law Firm (Shanghai), Mr. Li worked as a paralegal at the Shanghai office of Boss & Young from March 2003 to April 2005; as a marketing manager at Lenovo Group Limited from September 1999 to August 2000; and as a staff member at China National Arts & Crafts (Group) Corporation from July 1997 to June 1999. Mr. Li has provided legal services to more than 40 companies in their domestic and overseas listing and restructurings, and has nearly 20 years of extensive legal experience in listing. Mr. Li also serves as independent directors of Shanghai Anoky Group Co., Ltd. (Stock Code: 300067.SZ) and Impulse (Qingdao) Health Tech Co., Ltd. (Stock Code: 002899.SZ). Mr. Li obtained his master’s degree in law from Shanghai University of International Business and Economics, master’s degree in law from Chicago-Kent College of Law and EMBA from China Europe International Business School (CEIBS).
